Register for Isogenica’s upcoming webinar
Join Isogenica for the upcoming webinar with Nature on ‘VHH as building blocks for immune and tumour cell-targeting’, presented by Isogenica’s CSO Bill Eldridge.
This presentation will expand on the recent advances in the field of VHH-based therapeutics and highlight particular therapy applications where a naturally monovalent antibody domain structure can be combined to generate the next generation of biologics.
Specifically, it will answer the following questions:
What are the potential applications of VHH antibodies?
What are VHH and their unique characteristics which make them applicable as immune cell recruiting agents?
VHH-based Bispecifics: what differentiates them from the existing classes of bispecific antibodies.
Register for the webinar now to learn all about the incredible potential and latest developments of VHH in next generation therapeutics.
Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
T +44 1799 533 680